Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9809486rdf:typepubmed:Citationlld:pubmed
pubmed-article:9809486lifeskim:mentionsumls-concept:C0027756lld:lifeskim
pubmed-article:9809486lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:9809486lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:9809486lifeskim:mentionsumls-concept:C1516240lld:lifeskim
pubmed-article:9809486lifeskim:mentionsumls-concept:C0034284lld:lifeskim
pubmed-article:9809486lifeskim:mentionsumls-concept:C0296506lld:lifeskim
pubmed-article:9809486pubmed:issue5lld:pubmed
pubmed-article:9809486pubmed:dateCreated1998-12-23lld:pubmed
pubmed-article:9809486pubmed:abstractText1. We studied whether a new neurotrophic pyrimidine compound, MS-430, can increase the regeneration length of the transected sciatic nerve in a silicone chamber gap of 14 mm. 2. The average length of regenerated myelinated axons in ten cases was 9.0+/-0 mm in the control group, 2.8+/-1.9 mm in the 1 mg/kg/day of the MS-430 group and 5.0+/-5.1 mm in the 3 mg/kg/day of the MS-430 group, indicating that the average length was significantly larger in the 3-mg group than that in the control group (P<0.05). 3. The results clearly showed that the MS-430 has promoting effects on nerve regeneration.lld:pubmed
pubmed-article:9809486pubmed:languageenglld:pubmed
pubmed-article:9809486pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9809486pubmed:citationSubsetIMlld:pubmed
pubmed-article:9809486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9809486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9809486pubmed:statusMEDLINElld:pubmed
pubmed-article:9809486pubmed:monthNovlld:pubmed
pubmed-article:9809486pubmed:issn0306-3623lld:pubmed
pubmed-article:9809486pubmed:authorpubmed-author:NodaMMlld:pubmed
pubmed-article:9809486pubmed:authorpubmed-author:IkutaYYlld:pubmed
pubmed-article:9809486pubmed:authorpubmed-author:OchsGGlld:pubmed
pubmed-article:9809486pubmed:authorpubmed-author:AwayaAAlld:pubmed
pubmed-article:9809486pubmed:issnTypePrintlld:pubmed
pubmed-article:9809486pubmed:volume31lld:pubmed
pubmed-article:9809486pubmed:ownerNLMlld:pubmed
pubmed-article:9809486pubmed:authorsCompleteYlld:pubmed
pubmed-article:9809486pubmed:pagination821-4lld:pubmed
pubmed-article:9809486pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:meshHeadingpubmed-meshheading:9809486-...lld:pubmed
pubmed-article:9809486pubmed:year1998lld:pubmed
pubmed-article:9809486pubmed:articleTitleIncrease of nerve regeneration capacity by new neurotrophic pyrimidine derivative MS-430.lld:pubmed
pubmed-article:9809486pubmed:affiliationOrthopedic Surgery, Matsuyama Red Cross Hospital, Japan.lld:pubmed
pubmed-article:9809486pubmed:publicationTypeJournal Articlelld:pubmed